What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
Ryerson Holding (NYSE: RYI) finalises Olympic Steel acquisition as North American metals consolidation accelerates
Read More 5 minute read Pharma Industry News Can GSK’s Exdensur transform asthma biologics with just two doses per year? GSK’s Exdensur is now FDA approved as the first biannual biologic for severe asthma. Explore what this means for rivals, payers, and global strategy. byPallavi MadhirajuDecember 17, 2025